Citations

Clear

21 citation(s) found for "Martin, Paul".

Deciphering lung adenocarcinoma evolution and the role of LINE-1 retrotransposition
Yin, Jinhu , Leduc, Charles , Sholl, Lynette M. , McElderry, John, Hartman, Caleb , Rosenbaum, Jennifer, Colón-Matos, Frank J. , Miraftab, Mona , Caporaso, Neil E. , Wong, Maria Pik , Leung, Kin Chung, Hsiung, Chao A. , Chen, Chih-Yi, Edell, Eric S. , Santamaría, Jacobo Martínez, Mańczuk, Marta , Mukeria, Anush, Shangina, Oxana , Заридзе, Давид , Mates, Dana, Milosavljević, Saša , Savić, Milan , Gaborieau, Valérie , Hofman, Paul L. , Yang, Lixing , Shi, Jianxin , Brown, Kevin M. , Rothman, Nathaniel , Choi, Jiyeon , Lan, Qing , Wedge, David C. , Landi, Maria Teresa , Chen, Chih‐Yi , Manczuk, Marta , Chen, Chih-Yi , Leduc, Charles , Zhang, Tongwu , Zhao, Wei , Wirth, Christopher, Díaz‐Gay, Marcos , Cecati, Monia , Marchegiani, Francesca , Hoang, Phuc H. , Baine, Marina K , Travis, William D. , Joubert, Philippe , Sang, Jian , Klein, Alyssa , Khandekar, Azhar , Saha, Monjoy , Lee, Olivia W. , Jones, Kristine , Santamaría, Jacobo Martínez, Schabath, Matthew B. , Yendamuri, Sai S , Lissowska, Jolanta , Świątkowska, Beata , Holcátová, Ivana , Milosavljevic, Sasa , Bossé, Yohan , Gould Rothberg, Bonnie E , Christiani, David C. , Brennan, Paul Martin , Liu, Geoffrey , Hofman, Paul , Homer, Robert , Yang, Soo-Ryum , Pesatori, Angela C , Consonni, Dario , Zhu, Bin , Chanock, Stephen Jacob , Alexandrov, Ludmil B. , Cardelli, Maurizio , Nowak, Martin A.

Mayo Clinic

No container title available | March 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.14.643063 | PMID 40161734 Get It

ABSTRACT Understanding lung cancer evolution can identify tools for intercepting its growth. In a landscape analysis of 1024 lung adenocarcinomas (LUAD) with deep whole-genome sequencing integrated with multiomic data, we identified 542 LUAD that displayed diverse clonal architecture. In this group, we observed an interplay between mobile elements, endogenous and exogenous mutational processes, distinct driver genes, and epidemiological features. Our results revealed divergent evolutionary trajectories based on tobacco smoking exposure, ancestry, and sex. LUAD from smokers showed an abundance of tobacco-related C:G>A:T driver mutations in KRAS plus short subclonal diversification. LUAD in never smokers showed early occurrence of copy number alterations and EGFR mutations associated with SBS5 and SBS40a mutational signatures. Tumors harboring EGFR mutations exhibited long latency, particularly in females of European-ancestry (EU_N). In EU_N, EGFR mutations preceded the occurrence of other driver genes, including TP53 and RBM10. Tumors from Asian never smokers showed a short clonal evolution and presented with heterogeneous repetitive patterns for the inferred mutational order. Importantly, we found that the mutational signature ID2 is a marker of a previously unrecognized mechanism for LUAD evolution. Tumors with ID2 showed short latency and high L1 retrotransposon activity linked to L1 promoter demethylation. These tumors exhibited an aggressive phenotype, characterized by increased genomic instability, elevated hypoxia scores, low burden of neoantigens, propensity to develop metastasis, and poor overall survival. Re-activated L1 retrotransposition-induced mutagenesis can contribute to the origin of the mutational signature ID2, including through the regulation of the transcriptional factor ZNF695 , a member of the KZFP family. The complex nature of LUAD evolution creates both challenges and opportunities for screening and treatment plans.
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases
Brahmania, Mayur , Kuo, Alexander , Tapper, Elliot B. , Völk, Michael , Vittorio, Jennifer , Ghabril, Marwan , Morgan, Timothy R. , Kanwal, Fasiha , Parikh, Neehar D. , Mehta, Shivang , Goldberg, David S. , Duarte‐Rojo, Andrés , Paredes, Angelo H. , Sahota, Amandeep , McElroy, Lisa M. , Thomas, Charlie, Aslam, Saima , Ramakrishnan, Sudha , Flynn, Mary M. , Volk, Michael L , Vittorio, Jennifer M , Mehta, Shivang , Winder, Scott , Im, Gene , Goldberg, David , Lai, Jennifer , Duarte-Rojo, Andres , Paredes, Angelo H , Patel, Arpan , Sahota, Amandeep , McElroy, Lisa M , Wall, Anji E , Malinis, Maricar , Aslam, Saima , Simonetto, Douglas A , Ufere, Nneka N , Ramakrishnan, Sudha , Ibrahim, Yasmin , Asrani, Sumeet K , Serper, Marina , Ghabril, Marwan S , Parikh, Neehar D , Kanwal, Fasiha , Martin, Paul B. , Winder, Gerald Scott , Lai, Jennifer C. , Patel, Arpan , Wall, Anji , Simonetto, Douglas A. , Asrani, Sumeet K. , Serper, Marina

Mayo Clinic

Hepatology | March 27, 2024 | Volume: 80 | Issue: 3 | Pages: 742-753

10.1097/hep.0000000000000870 | PMID 38536021 Get It

The liver transplantation (LT) evaluation and waitlisting process is subject to variations in care that can impede quality. The American Association for the Study of Liver Diseases (AASLD) Practice Metrics Committee (PMC) developed quality measures and patient-reported experience measures along the continuum of pre-LT care to reduce care variation and guide patient-centered care. Following a systematic literature review, candidate pre-LT measures were grouped into 4 phases of care: referral, evaluation and waitlisting, waitlist management, and organ acceptance. A modified Delphi panel with content expertise in hepatology, transplant surgery, psychiatry, transplant infectious disease, palliative care, and social work selected the final set. Candidate patient-reported experience measures spanned domains of cognitive health, emotional health, social well-being, and understanding the LT process. Of the 71 candidate measures, 41 were selected: 9 for referral; 20 for evaluation and waitlisting; 7 for waitlist management; and 5 for organ acceptance. A total of 14 were related to structure, 17 were process measures, and 10 were outcome measures that focused on elements not typically measured in routine care. Among the patient-reported experience measures, candidates of LT rated items from understanding the LT process domain as the most important. The proposed pre-LT measures provide a framework for quality improvement and care standardization among candidates of LT. Select measures apply to various stakeholders such as referring practitioners in the community and LT centers. Clinically meaningful measures that are distinct from those used for regulatory transplant reporting may facilitate local quality improvement initiatives to improve access and quality of care.
Proceedings of the 28th Annual Congress of the International Liver Transplantation Society
Mathew, Johns Shaji , Shingina, Alexandra , Khan, Mohammad Qasim , Wilson, Elizabeth A. , Alconchel, Felipe , Hakeem, Abdul , Shankar, Sadhana , Patel, Dhupal , Keskin, Onur , Mazzola, Alessandra , Tanaka, Tomohiro , Victor, David W. , Yoon, Uzung , Vinaixa, Carmen , Kirchner, Varvara A. , Martin, Eléonora De , Ghobrial, R. Mark , Wilson, Elizabeth , Rammohan, Ashwin , Alconchel, Felipe , Hakeem, Abdul Rahman , Shankar, Sadhana , Patel, Dhupal , Keskin, Onur , Nasralla, David , Mazzola, Alessandra , Tanaka, Tomohiro , Victor, David , Yoon, Uzung , Yoon, Young-In , Vinaixa, Carmen , Kirchner, Varvara , De Martin, Eleonora , Ghobrial, Mark , Chadha, Ryan , Syn, Nicholas L. X. , Liu, Jiang , Patel, Madhukar S. , Chadha, Ryan , Khan, Mohammad Qasim

Mayo Clinic

Liver Transplantation | January 19, 2024 | Volume: 30 | Issue: 5 | Pages: 544-554

10.1097/lvt.0000000000000330 | PMID 38240602 Get It

The 2023 Joint International Congress of the International Liver Transplantation Society (ILTS), the European Liver and Intestine Transplant Association (ELITA), and the Liver Intensive Care Group of Europe (LICAGE) held in Rotterdam, the Netherlands, marked a significant recovery milestone for the liver transplant community after COVID-19. With 1159 participants and a surge in abstract submissions, the event focused on “Liver Disorders and Transplantation: Innovations and Evolving Indications.” This conference report provides a comprehensive overview of the key themes discussed during the event, encompassing Hepatology, Anesthesia and Critical Care, Acute Liver Failure, Infectious Disease, Immunosuppression, Pediatric Liver Transplantation, Living Donor Liver Transplantation, Transplant Oncology, Surgical Approaches, and Machine Perfusion. The congress provided a platform for extensive discussions on a wide range of topics, reflecting the continuous advancements and collaborative efforts within the liver transplant community.
Anakinra‐Associated Systemic Amyloidosis
Alehashemi, Sara , Dasari, Surendra , Metpally, Anvitha , Uss, Kat, Chen, Marcus Y. , Ahlman, Mark A. , Kim, Jeff , Wargo, Susannah, Kuhns, Douglas B. , Fink, Danielle , Jesus, Adriana de, Martin, Paul S. , Bolaños, Jonathan A. , Nasr, Samih H. , Goldbach‐Mansky, Raphaela , Goldbach-Mansky, Raphaela , McPhail, Ellen, Castelo‐Soccio, Leslie , Heller, Theo , Kellman, Peter , Chang, Richard Cheng-An , Lee, Chyi‐Chia Richard , McPhail, Ellen Darcy

Mayo Clinic

Arthritis & Rheumatology | July 25, 2023 | Volume: 76 | Issue: 1 | Pages: 100-106

10.1002/art.42664 | PMID 37488949 Get It

ObjectiveTo describe a 41‐year‐old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin‐1 receptor antagonist (IL‐1Ra) protein, anakinra, since the age of 28, who presented with golf‐ball size nodules at the anakinra injection sites, early satiety, new onset nephrotic syndrome in the context of normal markers of systemic inflammation.MethodsClinical history and histologic evaluation of biopsies of skin, gastric mucosa, and kidney with Congo‐red staining and proteomic evaluation of microdissected Congo red–positive amyloid deposits by liquid chromatography‐tandem mass spectrometry.ResultsThe skin, stomach, and kidney biopsies all showed the presence of Congo red–positive amyloid deposits. Mass spectrometry‐based proteomics demonstrated that the amyloid deposits in all sites were of AIL1RAP (IL‐1Ra protein)‐type. These were characterized by high spectral counts of the amyloid signature proteins (apolipoprotein AIV, apolipoprotein E, and serum amyloid P‐component) and the amyloidogenic IL‐1Ra protein, which were present in Congo red–positive areas and absent in Congo red–negative areas. The amino acid sequence identified by mass spectrometry confirmed that the amyloid precursor protein was recombinant IL‐1Ra (anakinra) and not endogenous wild‐type IL‐1Ra.ConclusionThis is the first report of iatrogenic systemic amyloidosis due to an injectable protein drug, which was caused by recombinant IL1Ra (anakinra).
E-AHPBA–ESSO–ESSR Innsbruck consensus guidelines for preoperative liver function assessment before hepatectomy
Primavesi, Florian , Maglione, Manuel , Cipriani, Federica , Denecke, Timm , Oberkofler, Christian E. , Dasari, B. , Heil, Jan , Sgarbură, Olivia , Søreide, Kjetil , Díaz-Nieto, Rafael, Geisel, Dominik , Henninger, Benjamin , Hessheimer, Amelia J. , Mole, Damian J. , Reiberger, Thomas , Schnitzbauer, Andreas A. , Sparrelid, Ernesto , Stockmann, Martin , Truant, Stéphanie , Aldrighetti, Luca , Braunwarth, Eva , D’Hondt, Mathieu , DeOliveira, Michelle L., Erdmann, Joris I. , Kaczirek, Klaus , Malik, Hassan , Öfner, Dietmar , Rahbari, Nuh N. , Göbel, Georg , Siriwardena, Ajith K. , Dasari, Bobby V M , Sgarbura, Olivia , Søreide, Kjetil , Lesurtel, Mickaël , Mole, Damian , Schnitzbauer, Andreas A , Aldrighetti, Luca , Erdmann, Joris I , Gruenberger, Thomas , Öfner, Dietmar , Siriwardena, Ajith K , Maier, Eva , Reiberger, Thomas , Cipriani, Federica , Oberkofler, Christian , Maglione, Manuel , Starlinger, Patrick , Fondevila, Constantino , Frampton, Adam E. , Lesurtel, Mickaël , Öllinger, Robert , Olthof, Pim , Schwarz, Christoph C. , Fuks, David , Gruenberger, Thomas , Stättner, Stefan

Mayo Clinic

British Journal of Surgery | July 20, 2023 | Volume: 110 | Issue: 10 | Pages: 1331-1347

10.1093/bjs/znad233 | PMID 37572099 Get It

Abstract Background Posthepatectomy liver failure (PHLF) contributes significantly to morbidity and mortality after liver surgery. Standardized assessment of preoperative liver function is crucial to identify patients at risk. These European consensus guidelines provide guidance for preoperative patient assessment. Methods A modified Delphi approach was used to achieve consensus. The expert panel consisted of hepatobiliary surgeons, radiologists, nuclear medicine specialists, and hepatologists. The guideline process was supervised by a methodologist and reviewed by a patient representative. A systematic literature search was performed in PubMed/MEDLINE, the Cochrane library, and the WHO International Clinical Trials Registry. Evidence assessment and statement development followed Scottish Intercollegiate Guidelines Network methodology. Results Based on 271 publications covering 4 key areas, 21 statements (at least 85 per cent agreement) were produced (median level of evidence 2− to 2+). Only a few systematic reviews (2++) and one RCT (1+) were identified. Preoperative liver function assessment should be considered before complex resections, and in patients with suspected or known underlying liver disease, or chemotherapy-associated or drug-induced liver injury. Clinical assessment and blood-based scores reflecting liver function or portal hypertension (for example albumin/bilirubin, platelet count) aid in identifying risk of PHLF. Volumetry of the future liver remnant represents the foundation for assessment, and can be combined with indocyanine green clearance or LiMAx® according to local expertise and availability. Functional MRI and liver scintigraphy are alternatives, combining FLR volume and function in one examination. Conclusion These guidelines reflect established methods to assess preoperative liver function and PHLF risk, and have uncovered evidence gaps of interest for future research.
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Barth, Matthew J. , Audino, Anthony , Blazin, Lindsay , Chung, Jong , Davies, Kimberly, Ding, Hilda, Ford, James B. , Galardy, Paul J. , Hanna, Rabi , Hayashi, Robert J. , Lee‐Miller, Cathy , Machnitz, Andrea Judit, Maloney, Kelly W. , Marks, Lianna J. , Martin, Paul L. , Pacheco, Martha, Reilly, Anne F. , Roshal, Mikhail , Song, Sophie X. , Weinstein, Joanna , Zarnegar‐Lumley, Sara , McMillian, Nicole R., Schonfeld, Ryan, Sundar, Hema, Blazin, Lindsay J , Xavier, Ana C , Armenian, Saro H. , Bloom, David E. , McCall, David C.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 9, 2022 | Volume: 20 | Issue: 11 | Pages: 1267-1275

10.6004/jnccn.2022.0057 | PMID 36351334 Get It

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Aggressive Mature B-Cell Lymphomas include recommendations for the diagnosis and management of pediatric patients with primary mediastinal large B-cell lymphoma (PMBL) and sporadic variants of Burkitt lymphoma and diffuse large B-cell lymphoma. PMBL is now considered as a distinct entity arising from mature thymic B-cells accounting for 2% of mature B-cell lymphomas in children and adolescents. This discussion section includes the recommendations outlined in the NCCN Guidelines for the diagnosis and management of pediatric patients with PMBL.
Author response: Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α
Mann, Shivani N. , Holte, Molly Nelson, Rothman, Alicia R, Sathiaseelan, Roshini , Mondal, Samim Ali , Agbaga, Martin‐Paul , Unnikrishnan, Archana , Subramaniam, Malayannan , Hawse, John R. , Huffman, Derek M. , Hadad, Niran , Freeman, Willard M. , Stout, Michael B

Mayo Clinic

No container title available | December 16, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.59616.sa2 Get It

Health benefits attributed to 17α-estradiol, a lifespan-extending compound, are mediated through estrogen receptor α
Mann, Shivani N. , Holte, Molly Nelson, Rothman, Alicia R, Sathiaseelan, Roshini , Mondal, Samim Ali , Agbaga, Martin‐Paul , Unnikrishnan, Archana , Subramaniam, Malayannan , Hawse, John R. , Huffman, Derek M. , Nelson Holte, Molly, Hawse, John, Freeman, Willard M , Stout, Michael B , Hadad, Niran , Freeman, Willard M.

Mayo Clinic

eLife | December 8, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.59616 | PMID 33289482 Get It

Metabolic dysfunction underlies several chronic diseases, many of which are exacerbated by obesity. Dietary interventions can reverse metabolic declines and slow aging, although compliance issues remain paramount. 17α-estradiol treatment improves metabolic parameters and slows aging in male mice. The mechanisms by which 17α-estradiol elicits these benefits remain unresolved. Herein, we show that 17α-estradiol elicits similar genomic binding and transcriptional activation through estrogen receptor α (ERα) to that of 17β-estradiol. In addition, we show that the ablation of ERα completely attenuates the beneficial metabolic effects of 17α-E2 in male mice. Our findings suggest that 17α-E2 may act through the liver and hypothalamus to improve metabolic parameters in male mice. Lastly, we also determined that 17α-E2 improves metabolic parameters in male rats, thereby proving that the beneficial effects of 17α-E2 are not limited to mice. Collectively, these studies suggest ERα may be a drug target for mitigating chronic diseases in male mammals.
Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis
Asrani, Sumeet K. , Trotter, James F. , Lake, Jack, Bonagura, Anthony, Cameron, Andrew M. , DiMartini, Andrea F. , Martin, Paul , Mathurin, Philippe , Mellinger, Jessica L. , Rice, John P. , Shah, Vijay H. , Winder, Scott, Klintmalm, Göran B. , DiMartini, Andrea , Im, Gene , Shah, Vijay H , Terrault, Norah , Winder, Scott , Asrani, Sumeet K , Lake, Jack, Ahmed, Aijaz , Gonzalez, Stevan A , Martin, Paul, Terrault, Norah A. , Wall, Anji

Mayo Clinic

Liver Transplantation | November 19, 2019 | Volume: 26 | Issue: 1 | Pages: 127-140

10.1002/lt.25681 | PMID 31743578 Get It

Liver transplantation (LT) for alcohol associated hepatitis (AH) remains controversial. We convened a consensus conference to examine various aspects of LT for AH. The goal was not to unequivocally endorse LT for AH; instead, it was to propose recommendations for programs that perform or plan to perform LT for AH. Criteria were established to determine candidacy for LT in the setting of AH and included the following: (1) AH patients presenting for the first time with decompensated liver disease that are nonresponders to medical therapy without severe medical or psychiatric comorbidities; (2) a fixed period of abstinence prior to transplantation is not required; and (3) assessment with a multidisciplinary psychosocial team, including a social worker and an addiction specialist/mental health professional with addiction and transplantation expertise. Supporting factors included lack of repeated unsuccessful attempts at addiction rehabilitation, lack of other substance use/dependency, acceptance of diagnosis/insight with a commitment of the patient/family to sobriety, and formalized agreement to adhere to total alcohol abstinence and counseling. LT should be avoided in AH patients who are likely to spontaneously recover. Short‐term and longterm survival comparable to other indications for LT must be achieved. There should not be further disparity in LT either by indication, geography, or other sociodemographic factors. Treatment of alcohol‐use disorders should be incorporated into pre‐ and post‐LT care. The restrictive and focused evaluation process described in the initial LT experience for AH worldwide may not endure as this indication gains wider acceptance at more LT programs. Transparency in the selection process is crucial and requires the collection of objective data to assess outcomes and minimize center variation in listing. Oversight of program adherence is important to harmonize listing practices and outcomes.
Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol
Richardson, Paul G. , Smith, Angela R. , Arai, Sally , Adams, Roberta H. , Martin, Paul , Abhyankar, Sunil , Gillio, Alfred P. , Lehmann, Leslie , Haut, Paul, Termuhlen, Amanda , Antin, Joseph H. , Spitzer, Thomas R. , Avigan, David , Hannah, Alison L., Iacobelli, Massimo , Soiffer, Robert J. , Group, Defibrotide Study, Richardson, Paul Gerard Guy , Grupp, Stephan A. , Kernan, Nancy A. , Grimley, Michael S. , Massaro, Joseph M. , Group, Defibrotide Study

Mayo Clinic

Blood | October 13, 2019 | Volume: 116 | Issue: 21 | Pages: 906-906

10.1182/blood.v116.21.906.906 Get It

Abstract Abstract 906 Background: Single-arm Phase 2 trials of DF in the treatment of severe VOD/MOF post-SCT demonstrated a complete response (CR) in 36–46% of patients (pts). A subsequent Phase 3 trial enrolling pts with more severe VOD (28%/24% with ventilator/dialysis dependence at study entry vs 5%/7%) demonstrated a CR of 24% compared to 9% in a matched Historical Control (HC); p=0.0148; Richardson ASH 2009). Given the life-threatening nature of VOD/MOF, DF was made available in the United States through a Treatment IND protocol (T-IND) in December 2007 to gather additional safety and response data. Methods: Pts were required to have a diagnosis of VOD based upon Baltimore criteria (total bilirubin ≥ 2.0 mg/dL with ≥ 2 of the following: hepatomegaly, ascites or 5% weight gain) with MOF (either renal and/or pulmonary failure). Pts without a Baltimore diagnosis could enroll with biopsy-proven evidence of VOD. Eligibility criteria were expanded to permit patients with late onset VOD (VOD diagnosed after 21 days (d) or VOD/MOF after 28d post-SCT). Key exclusion criteria included clinically significant bleeding or need for >1 pressor to maintain BP. CR was defined as bilirubin < 2 mg/dL + resolution of MOF. Mortality was assessed at D+100. DF was given at 6.25 mg/kg IV q6h (25 mg/kg/d); treatment duration was recommended for at least 21d. Results: This interim analysis is based on 104 pts enrolled between14Dec2007-29Sep2009 and treated at 36 institutions. Most sites (n=23) enrolled only 1–2 pts. Nearly all pts (n=98) had undergone prior SCT; 6 had prior chemotherapy only; and 29 pts had late onset VOD post-SCT. Of the SCT pts, 69 pts enrolled in the T-IND met eligibility criteria for the original Phase 3 trial. Baseline demographics included median age 17 years (range 0.1 – 66); 59% male; and 16% with prior SCT. The most common diagnosis was leukemia (30% AML; 22% ALL; 7% other leukemia). The majority of pts had undergone allogeneic SCT (88%) with conditioning consisting of cyclophosphamide (76%), busulfan (42%) and/or TBI (41%). Mean onset of VOD post-SCT was 17 days. At entry, 20% of pts were dialysis dependent; 28% were ventilator dependent. Mean number of days of DF administration was 20 (range 2–88). Of the 104 pts, 36 (35%) achieved a CR by D+100. For the various sub-populations, the CR by D+100 rate was 24% for pts with late-onset VOD (n=29); 35% for those pts undergoing SCT (n=98); and 39% for the 69 pts who matched the entry criteria for the Phase 3 trial. Comparison of this group of 69 pts to the Phase 3 HC showed a statistically improved outcome (p=0.0007). Similar to the Phase 3 results, the CR rate was higher in pts who were not on dialysis/ventilator at study entry (41% vs 23%). Although children had previously been noted to have a higher CR rate in prior studies, the CR rate in the T-IND was similar in children compared to adults (35% and 34%, respectively). Overall D+100 mortality rate equaled 61% (n=104). Comparing the 69 pts who met Phase 3 entry criteria, D+100 mortality was 58% (p=0.0465 compared to the HC using Kaplan Meier estimates by log-rank analysis). Toxicity proved manageable: 11 pts experienced a total of 13 drug-related AEs including pulmonary hemorrhage (n=5), GI hemorrhage (n=3), hypotension (n=2), rectal hemorrhage, cerebral hemorrhage and pulmonary alveolar hemorrhage (1 pt each). Overall, 10% of pts experienced a drug-related toxicity that led to discontinuation. Similar to the observation of decreased GvHD in pediatric pts undergoing SCT who received prophylactic DF compared to best supportive care, the incidence of all grade GvHD was relatively low (8%). Conclusions: In 104 pts with severe VOD/MOF enrolled at 36 US institutions, use of DF demonstrated a 35% CR by D+100. Comparing those pts who met criteria for the Phase 3 trial to the HC used in that study, D+100 CR and survival were significantly improved in this study population. DF-associated toxicities are consistent with prior studies. Following an amendment in 30Sep2009, entry criteria for the T-IND study were expanded to permit enrollment of pts without SCT (VOD post chemotherapy) as well as pts without MOF to evaluate earlier intervention. Analysis of this group will be performed separately. Enrollment into the T-IND study continues. Disclosures: Richardson: Gentium: Membership on an entity's Board of Directors or advisory committees. Massaro:Gentium: Consultancy. Hannah:Gentium: Consultancy. Iacobelli:Gentium: Employment.